Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip
ICD-10 C47.20 is a billable code used to indicate a diagnosis of malignant neoplasm of peripheral nerves of unspecified lower limb, including hip.
C47.20 refers to malignant tumors that arise from the peripheral nerves located in the lower limb, including the hip region. These tumors can be classified as soft tissue sarcomas, which are a diverse group of cancers originating from connective tissues. The peripheral nerves are responsible for transmitting signals between the brain and the rest of the body, and malignancies in this area can lead to significant functional impairment and pain. Grading of these tumors is crucial, as it helps determine the aggressiveness of the cancer and guides treatment options. Multidisciplinary management is essential for optimal patient outcomes, involving surgical intervention, radiation therapy, and chemotherapy, depending on the tumor's size, location, and grade. Accurate coding of this condition requires a thorough understanding of the clinical presentation, diagnostic imaging, and histopathological findings, as well as the treatment plan established by the healthcare team.
Detailed pathology reports, imaging studies, and treatment plans must be documented.
Patients presenting with pain, neurological deficits, or palpable masses in the lower limb.
Ensure accurate staging and grading are documented to support treatment decisions.
Operative reports detailing the extent of resection and any adjuvant therapies.
Surgical intervention for tumor resection or biopsy.
Document the surgical margins and any complications encountered during the procedure.
Used when a malignant peripheral nerve tumor is surgically excised.
Operative report detailing the tumor's location and size.
Oncology and surgical specialties must coordinate documentation for accurate coding.
Common symptoms include pain, weakness, numbness, and swelling in the affected limb. Patients may also experience neurological deficits depending on the tumor's location.
Grading is determined based on histological examination, assessing factors such as cellularity, mitotic activity, and necrosis. Higher grades indicate more aggressive tumors.
